ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Lipella Pharmaceuticals Inc. (LIPO) stock declined over -1.60%, trading at $2.15 on NASDAQ, down from the previous close of $2.19. The stock opened at $2.17, fluctuating between $2.06 and $2.19 in the recent session.
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Employees | 5 |
Beta | 0.15 |
Sales or Revenue | $449.62K |
5Y Sales Change% | 3.91% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |